Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine extension study in pediatric autism
NCT01592773Phase 2Terminated
- Sponsor
- Forest Laboratories
- Start
- Oct 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of memantine in Autism Spectrum Disorder (ASD), sponsored by Forest Laboratories. Primary endpoint: Patients With Any Treatment-emergent Adverse Event at 48 weeks. Started Oct 2012; status: terminated.
02
Drugs
memantine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01592773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592773.